Tumor Mutation Burden in Patients with Non-Squamous NSCLC: Current Status

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

GRACE

cancergrace.org

Podcast Series
Targeted Therapies in Lung Cancer 2023
ASCO® 2023
Lung Cancer OncTalk
Blood Cancer OncTalk
2022 Melanoma Video Library
OncTalk 2022
ASCO Lung Review 2022
ASCO and ESMO Lung Recap
2021 Targeted Therapies Patient Forum
COVID-19
Lung
Hematologic Oncology
Head and Neck
Brain
Palliative
Genitourinary
General
Breast

Playback speed

10 seconds

Tumor Mutation Burden in Patients with Non-Squamous NSCLC: Current Status

By GRACE FEATURING Sandip Patel

0 views

January 17, 2019

Comments 0

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Child-Pugh Classification and its Role in Treatment Decisions in Pat…

Feat. P. Gholam

Lung

04:01

GRACE

Lung Resection in Early Stage NSCLC: An Overview

Feat. C. Jeffrey Yang

05:58

GRACE

Future Goals of mNSCLC Treatment

Feat. P. Iyengar

06:13

GRACE

The NRG-LU Trial: Maintenance Systemic Therapy vs. Local Consolidati…

Feat. P. Iyengar

06:14

GRACE

Using Radiation to Improve Outcomes and QoL in Patients With mNSCLC

Feat. P. Iyengar

02:41

GRACE

Staging Disease: How Oncologists Stage NSCLC

Feat. I. Dagogo-Jack, M. Das, C. Jeffrey Yang

03:19

GRACE

Biomarkers in NSCLC

Feat. I. Dagogo-Jack, M. Das, C. Jeffrey Yang

06:09

GRACE

Perioperative vs. Preoperative Surgery in NSCLC

Feat. I. Dagogo-Jack, M. Das, C. Jeffrey Yang

03:25

GRACE

Antibody Drug Conjugates and How They Are Used in NSCLC

Feat. L. Bazhenova

02:36

GRACE

ADC Treatment in NSCLC

Feat. L. Bazhenova

03:15

GRACE

Bispecific Antibodies in Lung Cancer

Feat. L. Bazhenova

02:52

GRACE

Amivantamab in 1L Advanced NSCLC With EGFR exon 20 Insertion Mutatio…

Feat. L. Bazhenova

05:47

GRACE

Treatment Options for EGFR+ NSCLC

Feat. I. Dagogo-Jack, N. Vokes

03:42

GRACE

Surgical Options for Stage IV NSCLC With Brain Metastases: 60 y/o Wo…

Feat. I. Dagogo-Jack, J. Reuss

06:02

GRACE

Neoadjuvant Chemo +/- Nivo for Patients With Early Stage NSCLC: Case…

Feat. I. Dagogo-Jack, J. Reuss

03:21

GRACE

Treating Stage III NSCLC: Case-Based Panel Discussion

Feat. I. Dagogo-Jack, K. Arbour

03:44

GRACE

How Oncologists Stage Disease - Case-Based Panel Discussion: 50 y/o …

Feat. I. Dagogo-Jack, J. Reuss, N. Vokes, K. Arbour

09:37

GRACE

Is Broad NGS the Standard of Care in Advanced NSCLC?

Feat. I. Dagogo-Jack, M. Marmarelis, A. Sacher, A. Hegde

05:27

GRACE

Neoadjuvant Therapy vs. Adjuvant Therapy in NSCLC: What Is the Futur…

Feat. J. West, E. Rodriguez, R. Shah, N. Duma

05:38

GRACE

Surgical vs. Nonsurgical Treatment in Early NSCLC

Feat. J. West, E. Rodriguez, R. Shah, N. Duma

07:28

CancerGRACE

Early Stage NSCLC: PD-L1 and Durvalumab

Feat. J. West, E. Rodriguez, R. Shah, N. Duma

04:35

GRACE

Testing in Potentially Resectable & Unresectable Locally Advance…

Feat. J. West, E. Rodriguez, R. Shah, N. Duma

22:49

CancerGRACE

The Need for Broad Molecular Testing for Driver Mutations in NSCLC

Feat. J. Gainor

26:08

GRACE

NSCLC Frontline Therapy for Uncommon Mutations: Overview of RET, NTR…

Feat. J. Gainor

06:15

CancerGRACE

Expert Discussion on Targeted Therapy for mNSCLC: Can ALK Inhibitors…

Feat. J. West

18:10

GRACE

A Case of a NSCLC KRAS 71 y/o Female With Underlying Autoimmune Cond…

Feat. S. Liu, J. Brahmer, B. Levy

15:42

CancerGRACE

Expert Analysis of 1L EGFR+ Advanced NSCLC Options: 1st Gen Gefitini…

Feat. J. Weiss

10:33

GRACE

Targeted Therapy for EGFR+ NSCLC: How Do We Think About Acquired Res…

Feat. Z. Piotrowska

18:15

CancerGRACE

Targeted Therapy for EGFR+ NSCLC: What Are the Current Options Upon …

Feat. Z. Piotrowska

05:41

GRACE

ASCO Expert Discussion on Malignant Pleural Mesothelioma: Does Durva…

Feat. J. West, H. Yu, D. Spigel

05:47

GRACE

ASCO Roundtable on 2L Malignant Pleural Mesothelioma: How Encouragin…

Feat. J. West, H. Yu, D. Spigel

10:25

CancerGRACE

IO for Unresectable Stage 3 NSCLC: Does Durvalumab Help Patients? Wh…

Feat. M. Das

08:13

CancerGRACE

2020 ASCO Highlights on RT+ Chemo in LS-SCLC: Is There a Difference …

Feat. J. West, H. Yu, D. Spigel

16:22

GRACE

2020 ASCO ADAURA Trial Update on Adjuvant Osimertinib in EGFR+ NSCLC…

Feat. H. Yu, D. Spigel, J. West

11:28

CancerGRACE

2020 ASCO Update on 1L Advanced NSCLC: Is Nivo + Ipi + Limited Cours…

Feat. H. Yu, D. Spigel, J. West

11:22

CancerGRACE

2020 ASCO Update on Advanced NSCLC: What Is the Role for Nivolumab/I…

Feat. H. Yu, D. Spigel, J. West

09:02

CancerGRACE

2020 ASCO Update on MET/RET+ NSCLC: How Promising Are Capmatinib &am…

Feat. H. Yu, D. Spigel, J. West

08:25

CancerGRACE

2020 ASCO Update on HER2+ NSCLC: Is There a Promising Clinical Activ…

Feat. H. Yu, D. Spigel, J. West

12:16

CancerGRACE

2020 ASCO Update on EGFR+ NSCLC: Does Upfront SBRT to Sites at Diagn…

Feat. H. Yu, D. Spigel, J. West

08:16

CancerGRACE

ASCO 2020 Updates on PD-L1 NSCLC: Is Tiragolumab+Atezo Beneficial fo…

Feat. J. West, H. Yu, D. Spigel

05:32

GRACE

2020 Updates on SCLC: Have We Progressed in the Treatment of Relapse…

Feat. T. Owonikoko

05:16

CancerGRACE

Liquid Biopsy in NSCLC: Does Adding Liquid Biopsy to Tissue Testing …

Feat. C. Aggarwal

06:45

GRACE

SCLC Updates: What Are the Leading Immunotherapy Options?

Feat. S. Liu

05:38

GRACE

Expert Discussion on mNSCLC: What Are the Leading Treatment Options …

Feat. S. Liu

05:45

GRACE

2020 Update on Molecular Abnormalities in NSCLC: How Do MET Exon 14 …

Feat. J. Bauml

05:56

GRACE

The Role of IO for NSCLC Patients With Driver Mutations: What Data D…

Feat. B. Levy

07:43

CancerGRACE

2020 Update on Targeted Therapies in NSCLC PD-L1 Expression: What Ar…

Feat. M. Das

07:55

GRACE

Non-Small Cell Lung Cancer: Is Immunotherapy Safe for Frail Patients…

Feat. M. Gubens

05:13

GRACE

Does Immunotherapy Have Activity in Malignant Pleural Mesothelioma?

Feat. M. Das

06:15

CancerGRACE

Non-Small Cell Lung Cancer: How Does a Positive HER2 Mutation Affect…

Feat. J. West, J. Riess, S. Padda

06:03

GRACE

ALK+ NSCLC With High PD-L1. What Is the First Line Treatment for Pot…

Feat. J. West, J. Riess, S. Padda

06:00

CancerGRACE

What Is the Importance of MET Amplification Level in EGFR+ NSCLC Wit…

Feat. C. McCoach, H. Wakelee, J. West

03:45

GRACE

NSCLC EGFR Mutation Treated With Tagrisso: Progression While on Trea…

Feat. C. McCoach, H. Wakelee, J. West

07:30

CancerGRACE

NSCLC EGFR Mutation and the FLAURA Trial: Is There a Difference in D…

Feat. C. McCoach, H. Wakelee, J. West

08:20

GRACE

EGFR + NSCLC: Is There a Place for Chemo and the Inclusion of Immuno…

Feat. J. West, H. Wakelee, C. McCoach

04:14

CancerGRACE

EGFR Mutation and High and High PD-L1 in NSCLC: What is the Role of …

Feat. C. McCoach, H. Wakelee, J. West

05:18

CancerGRACE

Non-Small Cell Lung Cancer: What Are the Recommended Treatments for …

Feat. C. McCoach, H. Wakelee, J. West

05:04

CancerGRACE

NSCLC With EGFR Mutation: What Are the Treatment Options with Oligop…

Feat. C. McCoach, H. Wakelee, J. West

07:12

CancerGRACE

NSCLC With EGFR Mutation: Is There a Place for Chemotherapy and an E…

Feat. C. McCoach, H. Wakelee, J. West

05:52

CancerGRACE

NSCLC With EGFR Uncommon Exon 20 Mutation: Suggested Treatments, Tar…

Feat. C. McCoach, H. Wakelee, J. West

04:20

GRACE

The Challenges of Potential Pneumonitis Following Durvalumab in Stag…

Feat. M. Gubens, J. West, M. Das

06:03

CancerGRACE

Would IO Be Beneficial for Stage 3 NSCLC Patient with PDL1-0 After S…

Feat. M. Gubens, J. West, M. Das

08:02

CancerGRACE

Best Schedule for Durvalumab for Older Patient in Stage 3 NSCLC Afte…

Feat. J. West, M. Gubens, M. Das

05:12

CancerGRACE

Unresectable NSCLC: What Is TMB and Does it Add Significant Benefit …

Feat. M. Gubens, J. West, M. Das

08:50

GRACE

Does Checkmate 227's Suggestion of an IO Combination of Ipi + N…

Feat. M. Gubens, J. West, M. Das

10:58

CancerGRACE

Should Molecular Tests Be Considered in Stage 3 NSCLC and Would Outc…

Feat. M. Gubens, J. West, M. Das

09:22

CancerGRACE

Case of 60 y/o Woman with ALK Positive Metastatic NSCLC: Approach to…

Feat. S. Padda, J. Riess, J. West

06:14

GRACE

Case of ALK Positive Patient with Asymptomatic Brain Metastases: Is …

Feat. S. Padda, J. Riess, J. West

09:45

GRACE

Treatment for NSCLC Patient Who Developed Resistance to ALK Inhibito…

Feat. S. Padda, J. Riess, J. West

11:11

GRACE

Is the Standard Treatment the Best Approach for Stage 3 Frail Patien…

Feat. M. Gubens, J. West, M. Das

06:43

CancerGRACE

Should We Continue the ALK Inhibitor in NSCLC Patient with Brain Met…

Feat. S. Padda, J. Riess, J. West

10:53

CancerGRACE

Is There a Role for Combination Therapies Like Chemo/Radio and IO fo…

Feat. S. Padda, J. Riess, J. West

09:53

GRACE

Stage 3 NSCLC - Standard Concurrent Chemo + Radiation, Followed by I…

Feat. M. Gubens, J. West, M. Das

11:27

CancerGRACE

Stage 3 NSCLC: Is the Standard Treatment of Chemo and Radiation Foll…

Feat. M. Gubens, J. West, M. Das

11:26

CancerGRACE

Case Based Discussion on Stage 3 NSCLC: Should We Do Molecular Tests…

Feat. M. Gubens, J. West, M. Das

05:24

GRACE

CancerGRACE's ASCO 2019 Update on Lung Cancer: How Promising is…

Feat. J. West, B. Levy, C. Aggarwal

05:32

CancerGRACE

CancerGRACE's ASCO 2019 Update on Lung Cancer: Short Discussion…

Feat. J. West, B. Levy, C. Aggarwal

06:02

CancerGRACE

CancerGRACE's ASCO 2019 Update on Lung Cancer: Circulating Tumo…

Feat. J. West, B. Levy, C. Aggarwal

05:53

CancerGRACE

CancerGRACE's ASCO 2019 Update on Lung Cancer: Retrospective An…

Feat. J. West, B. Levy, C. Aggarwal

03:55

CancerGRACE

CancerGRACE's ASCO 2019 Update on Stage IV NSCLC: New Targets -…

Feat. J. West, B. Levy, C. Aggarwal

06:33

CancerGRACE

CancerGRACE's ASCO 2019 Highlights and New Approaches in Stage …

Feat. J. West, B. Levy, C. Aggarwal

07:14

CancerGRACE

CancerGRACE's ASCO 2019 Highlights and New Approaches in Stage …

Feat. J. West, B. Levy, C. Aggarwal

06:33

CancerGRACE

CancerGRACE's 2019 ASCO Highlights in Advanced NSCLC: What is t…

Feat. J. West, B. Levy, C. Aggarwal

06:38

CancerGRACE

CancerGRACE's 2019 ASCO Highlights on Adjuvant Afatinib in Stag…

Feat. J. West, B. Levy, C. Aggarwal

07:26

CancerGRACE

CancerGRACE's 2019 ASCO Highlights on Stage I NSCLC Adjuvant Ch…

Feat. J. West, B. Levy, C. Aggarwal

21:24

GRACE

Is There a Role for IO in EGFR+ Metastatic Lung Cancer?

Feat. H. Yu

47:56

CancerGRACE

Initial Treatment and Acquired Resistance in Advanced Lung Cancer &a…

Feat. J. Bauml, J. Sabari

21:58

CancerGRACE

Q&A on Targeted Therapies in Advanced Lung Cancer

Feat. J. Bauml

19:19

GRACE

Introduction to Next Generation Sequencing in Metastatic Lung Cancer…

Feat. J. Bauml

23:26

CancerGRACE

EGFR Initial Treatment and Acquired Resistance in Advanced NSCLC

Feat. H. Yu

09:30

GRACE

Q&A on EGFR Initial Treatment and Acquired Resistance in Advance…

Feat. H. Yu

07:53

CancerGRACE

Optimal First Line Treatment of EGFR+ Advanced NSCLC: First and Seco…

Feat. J. West

18:32

CancerGRACE

Optimal First Line Treatment of EGFR+ Advanced NSCLC: Osimertinib vs…

Feat. J. West

17:04

CancerGRACE

Optimal First Line Treatment of EGFR+ Advanced NSCLC: Dacomitinib, E…

Feat. J. West

17:10

CancerGRACE

Targeted Therapies in Advanced Lung Cancer: What is the Role of Rebi…

Feat. H. Borghaei

26:54

CancerGRACE

Discussion/Q&A on Targeted Therapies in Advanced Lung Cancer

Feat. H. Borghaei

15:23

GRACE

Targeted Therapies in Metastatic NSCLC: Liquid Biopsies as a New Opt…

Feat. C. Aggarwal

02:13

CancerGRACE

Immunotherapy in Stage lll NSCLC - The Pacific Trial and Imfinzi

Feat. K. Kelly

01:54

CancerGRACE